Skip to main content

Table 2 Anatomic location of measurable uninjected lesions in talimogene laherparepvec study

From: Systemic versus local responses in melanoma patients treated with talimogene laherparepvec from a multi-institutional phase II study

 

Any

Evaluablea

n (%)

n (%)

Any uninjected non-visceral, number of patients (%)

49 (100)

42 (100)

Any non-visceral, number of patients (%)

48 (98.0)

39 (92.9)

 Head/Neck, Front, number of lesions (%)

2 (4.1)

1 (2.4)

 Head/Neck, Back

1 (2.0)

1 (2.4)

 Head/Neck, Right

4 (8.2)

4 (9.5)

 Head/Neck, Left

4 (8.2)

4 (9.5)

 Trunk, Front

13 (26.5)

10 (23.8)

 Trunk, Back

6 (12.2)

5 (11.9)

 Lower Limb, Right

5 (10.2)

5 (11.9)

 Lower Limb, Left

8 (16.3)

8 (19.0)

 Upper Limb, Right

4 (8.2)

3 (7.1)

 Upper Limb, Left

2 (4.1)

1 (2.4)

 Right Hand, Palm

1 (2.0)

1 (2.4)

 Right Hand, Back

1 (2.0)

1 (2.4)

 Groin

2 (4.1)

2 (4.8)

 Lymph node, specify

21 (42.9)

16 (38.1)

 Other

16 (32.7)

8 (19.0)

Any visceral, number of patients (%)

23 (46.9)

15 (35.7)

 Eye, number of lesions (%)

1 (2.0)

0 (0.0)

 Brain

3 (6.1)

0 (0.0)

 Lung

17 (34.7)

12 (28.6)

 Gastrointestinal Tract

3 (6.1)

1 (2.4)

 Kidney

3 (6.1)

0 (0.0)

 Adrenal

4 (8.2)

1 (2.4)

 Liver

8 (16.3)

4 (9.5)

 Pancreas

3 (6.1)

2 (4.8)

 Spleen

4 (8.2)

0 (0.0)

  1. Denominator is the total number of patients. Patients may have multiple lesions
  2. aEvaluable indicates at least 2 assessments with valid measurements
  3. All patients received at least one dose of talimogene laherparepvec